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Tuberculosis (TB) is a major infectious disease killing nearly two million people, mostly in developing
countries, every year. The increasing incidence of resistance of Mycobacterium tuberculosis strains to the
most-effective (ﬁrst-line) anti-TB drugs is a major factor contributing to the current TB epidemic. Drug-
resistant strains have evolved mainly due to incomplete or improper treatment of TB patients. Resistance
of M. tuberculosis to anti-TB drugs is caused by chromosomal mutations in genes encoding drug targets.
Multidrug-resistant (resistant at least to rifampin and isoniazid) strains of M. tuberculosis (MDR-TB)
evolve due to sequential accumulation of mutations in target genes. Emergence and spreading of MDR-TB
strains is hampering efforts for the control and management of TB. The MDR-TB is also threatening World
Health Organization’s target of tuberculosis elimination by 2050. Proper management of MDR-TB relies
on early recognition of such patients. Several diagnostic methods, both phenotypic and molecular, have
been developed recently for rapid identiﬁcation of MDR-TB strains from suspected patients and some are
also suitable for resource-poor countries. Once identiﬁed, successful treatment of MDR-TB requires
therapy with several effective drugs some of which are highly toxic, less efﬁcacious and expensive.
Minimum treatment duration of 18e24 months is also long, making it difﬁcult for health care providers
to ensure adherence to treatment. Successful treatment has been achieved by supervised therapy with
appropriate drugs at institutions equipped with facilities for culture, drug susceptibility testing of MDR-
TB strains to second-line drugs and regular monitoring of patients for adverse drug reactions and
bacteriological and clinical improvement.
 2010 Elsevier Ltd. All rights reserved.Educational aims
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rved.Introduction
The morbidity and mortality associated with tuberculosis (TB)
continue to remain high despite intense worldwide efforts. Two
major factors that are sustaining the current TB epidemic include
expanding human immunodeﬁciency virus (HIV) infection and its
association with active TB disease and increasing resistance of
Mycobacterium tuberculosis strains to the most-effective (ﬁrst-line)
anti-TB drugs.1 Other factors that have also contributed include
population expansion, poor case detection and cure rates in
impoverished countries, active transmission in overcrowded
hospitals, prisons and other public places, immigration from high
incidence countries, drug abuse and homelessness. Active disease
patients with sputum-positive pulmonary TB are the main source
of infection in communities. Although an effective immune
response arrests multiplication of M. tuberculosis soon after
infection in majority of cases, only w10% individuals eradicate the
pathogen completely while w90% only succeed in containment of
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Organization (WHO) has estimated that nearly a third of the world
population is now infected with M. tuberculosis and 5e10% of the
infected individuals will develop active TB disease during their
lifetime. However, the risk of developing active disease is
5e15% every year and lifetime risk is w50% in HIV-coinfected
individuals.3
In 2006, 9.2 million new active disease cases (4.1 million being
sputum smear-positive) corresponding to an estimated incidence
of 139 per 100,000 population occurred throughout the world.1
Only half of these cases were actually reported while the rest
were based on assessments of effectiveness of surveillance
systems. The highest incidence rate (363 per 100,000 population)
was recorded for the African region, mainly due to high prevalence
of HIV infection. The 22 high burden (11 Asian, 9 African, 1 South
American and 1 East European) countries accounted for >84% of
all active TB cases worldwide. The lowest incidence rates (<20
cases per 100,000) were recorded for some developed, rich
countries. Nearly 700,000 (7.6%) of 9.2 million TB patients were
coinfected with HIV andw0.5 million cases of multidrug-resistant
TB (MDR-TB, deﬁned as infection with M. tuberculosis strains
resistant at least to rifampin, RIF and isoniazid, INH) occurred in
2006. Globally, the total prevalent TB cases in 2006 were 14.4
million that resulted in 1.7 million deaths (w95% occurring in
developing countries).1
Emergence of drug-resistant TB
The problem of drug-resistant TB is not new. In 1948, the British
Medical Research Council reported that the mortality rates in
pulmonary TB patients treated or not treated with streptomycin
(SM) were the same, however, most patients in the treated group
had died of relapse with SM-resistant strains.4 Standard short-
course chemotherapy with multiple drugs developed in 1960s and
1970s effectively kills all bacilli localized in different environments
(e.g. pulmonary cavities, pus, solid caseous material, immune cells)
including naturally occurring monodrug-resistant strains (as they
are killed by other drugs) and controls the emergence of multidrug-
resistant strains.5,6
Successful treatment of fully susceptible TB depends on
combination of drugs and duration of therapy, cost, and drug’s side
effects. Conversion of culture-positive to culture-negative sputum
within 2 months and subsequent clearing of ﬁltrates on chest
radiograph are positive signs while positive sputum cultures after 4
months of multidrug therapy indicate treatment failure.7 Treat-
ment failure is due to multiple factors (including, among other,
incomplete or inappropriate therapy) and results in persistence of
the disease mainly due to emergence of drug resistance (acquired
resistance). Primary resistance occurs when the resulting
M. tuberculosis strain is transmitted to a new host, as it causes TB
that is already resistant to the indicated drug(s).1,2 Major factors
associated with drug resistance development include presence of
cavitation together with smear-positive sputum and positive
sputum culture, non-adherence to therapy due to multiple factors
(such as cost of drugs, long duration andmultiple drug combination
used in treatment regimens and drug related adverse reactions),
treatment failures, coinfection with HIV, inadequate resources in
high burden countries, and prior history of treatment with anti-TB
drugs.1,7e9 The M. tuberculosis W/Beijing genotype has strong
association with MDR phenotype.10 Simultaneous treatment of
HIV-TB coinfection may lead to malabsorption and suboptimal
therapeutic blood levels of RIF and INH (despite adherence to
therapy) that facilitate the development of drug-resistant TB and
MDR-TB.3,9 The malabsorption of anti-TB drugs may also occur in
patients with some other underlying diseases.11,12Global epidemiology of MDR-TB
Four successive reports of Global Projects on Antituberculosis
Drug Resistance Surveillance sponsored byWHOwere published in
1997, 2001, 2006 and 2008. The latest report collected drug
susceptibility testing (DST) data for INH, RIF, SM and ethambutol
(EMB) from 93 settings in 81 countries during 2002e2007 and
showed that resistance to at least one anti-TB drug (any resistance)
among new TB cases was lower (varying from 0% to 56%) than in
previously treated TB patients (varying from 0% to 86%).9 The
worldwide average for any resistance, INH resistance and MDR
among all TB cases were estimated to be 20%, 13.3% and 5.3%,
respectively. The rates of resistance for any drug, INH and MDR
were higher in retreatment versus new TB cases. The data showed
that 489139 cases of MDR-TB occurred in 2006 representing 4.8% of
all TB cases. The highest percentage of MDR-TB cases were esti-
mated for countries of Eastern Europe (19.2%) followed by Western
Paciﬁc region (7%) and Southeast Asia (4.3%). The data also showed
that compared to the previous report,13 the burden ofMDR-TB cases
declined in USA and Hong Kong, remained stable in several Euro-
pean countries and increased in some developing countries.9
The MDR-TB is a major threat to global public health as it is
difﬁcult to treat and often results in relapse or treatment failure.14,15
It is also a risk factor for the emergence of XDR-TB (deﬁned as
infection with MDR-TB strains additionally resistant either to
a new-generation ﬂuoroquinolone and an injectable agent or to
three of the six main classes of second-line drugs).16 In 2006, nearly
10% of all MDR-TB cases in the former Soviet Union countries
(ranging from 4% in Armenia to 24% in Estonia) were XDR-TB.9 In
South Africa, 996 of 17615 (5.6%) of MDR-TB cases were also XDR-
TB. Although 50 countries have already reported one or more cases
of XDR-TB, there is no information for several other countries that
have a high incidence of MDR-TB.17 The emergence of XDR-TB is
extremely worrisome as it is more difﬁcult to treat than MDR-TB in
developed countries and is virtually untreatable in developing
countries. An outbreak of XDR-TB in South Africa was highly
lethal.18
Anti-TB drugs: mechanism of action and resistance
A better understanding of drug resistance mechanisms in
M. tuberculosis is crucial for the development of rapid methods for
drug resistance detection and new anti-TB drugs to treat MDR-TB/
XDR-TB patients. Early molecular studies identiﬁed katG (encoding
catalaseeperoxidase) and rpoB (encoding b-subunit of RNA poly-
merase) genes as major targets conferring resistance of M. tuber-
culosis to INH and RIF, respectively.19,20 The current knowledge of
the genes and their target regions involved in mediating resistance
of M. tuberculosis to important anti-TB drugs is summarized in
Table 1.
Isoniazid (INH), a pro-drug, has the highest activity (MIC
<0.05 mg/ml) against actively dividing M. tuberculosis.19 It is acti-
vated by catalaseeperoxidase encoded by katG. Activated INH
mainly targets NADH-speciﬁc enoyl-acyl carrier protein (ACP)
reductase (encoded by inhA) and b-ketoacyl ACP synthase (encoded
by kasA) involved in mycolic acid synthesis. Depletion of mycolic
acids results in bacterial killing.19,21
The molecular basis of resistance to INH involves a variety of
mutations (insertions, deletions and point mutations) in several
genes. The main targets include katG and the regulatory and coding
region of inhA.19,21,22 Mutations in other genes are either compen-
satory resulting from the loss of catalaseeperoxidase activity or
have a minor role.23 Despite the complexity, high- and low-level
resistance to INH is mainly due to mutations within the katG and
inhA regulatory region.19,21e24 The katG gene mutations occur
Table 1
Important genes (and their encoded products) of M. tuberculosis conferring resis-
tance to ﬁrst-line and some second-line anti-TB drugs.
Anti-TB
drug(s)
Gene
target
Encoded protein
or RNA product
Major target
region in
encoded product
Level of
resistance
RIF rpoB b-Subunit of RNA
polymerase
81-bp HSR High
INH katG Catalase/peroxidase Entire gene High
INH/ETH inhA Enoyl-acyl carrier
protein reductase
Upstream
regulatory region
Low
PZA pncA Pyrazinamidase Several codons High
EMB embB Arabinosyltransferase Several codons High
EMB embA Arabinosyltransferase Several codons High
EMB iniA Isoniazid-inducible
gene
Few codons High
SM rrs 16S rRNA Several nucleotides Low
SM rpsL Ribosomal
Protein S12
Codons 43 and 48 High
FQs gyrA A subunit of DNA
gyrase
Few codons High
FQs gyrB B subunit of DNA
gyrase
Few codons High
KAN/AMI rrs 16S rRNA Position 1401 or 1484 High
CAP/VIO rrs 16S rRNA Position 1402 or 1484 High
CAP/VIO tlyA Cytotoxin/haemolysin
homologue
Several codons High
RIF, rifampin; INH, isoniazid; ETH, ethionamide; PZA, pyrazinamide; EMB, etham-
butol; SM, streptomycin; FQs, ﬂuoroquinolones (ciproﬂoxacin, oﬂoxacin, levo-
ﬂoxacin); KAN, kanamycin; AMI, amikacin; CAP, capreomycin; VIO, viomycin; and
HSR, hot-spot region.
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(katG315). The mutations in inhA regulatory region occur mostly at
positions 15 and 8 (relative tomabA translational start site). The
frequency of katG315 (w50e95%) and inhA regulatory region
(w6e30%) mutations vary considerably depending upon the
ethnicity of the infected TB patient/geographical location where
M. tuberculosis strain is isolated (Table 2).24e28 Some INH-resistant
strains do not have an identiﬁable mutation implying that addi-
tional targets are involved.23,24
Rifampin (RIF), a lipophilic rifamycin derivative, binds to
b-subunit of RNA polymerase (encoded by rpoB) and inhibits RNA
transcription and consequently, protein synthesis in
M. tuberculosis.20,23 Mutations in rpoB gene confer RIF resistance by
affecting drug binding. Monoresistance to RIF is rare except in
HIV-coinfected patients and RIF resistance is often a surrogate
marker for MDR-TB since w85e90% RIF-resistant strains are also
resistant to INH.3,20,29e32 Nearly 90e95% of RIF-resistant strains
carry missense mutations or small in-frame insertions/deletions
within an 81-bp hot-spot region (HSR) mainly involving rpoBTable 2
Frequency of mutations in main target region and most commonly mutated codon/
nucleotide in target gene conferring resistance to anti-TB drugs in M. tuberculosis.
Anti-TB
agent(s)
Gene
target
Main target
region
Relative
frequency
in resistant
strains
Most common mutation at
Codon/nucleotide Frequency
RIF rpoB 81-bp HSR 90e95% Codon 531 30e75%
INH katG Entire gene 50e95% Codon 315 50e95%
INH/ETH inhA Regulatory region 6e30% Nucleotide (-)15a 6e30%
PZA pncA Several codons 62e97% No dominant mutation
EMB embB Several codons 47e89% Codon 306 20e70%
SM rpsL Codons 43 and 48 40e95% Codon 43 40e90%
RIF, rifampin; INH, isoniazid; ETH, ethionamide; PZA, pyrazinamide; EMB, etham-
butol; SM, streptomycin; and HSR, hot-spot region.
a Nucleotide situated relative to the start of mabA open reading frame of mabA-
inhA operon.codons 531, 526 and 516 (Table 2).20,30e34 Resistance in w5e10%
RIF-resistant isolates is due to mutations in N-terminal or other
regions of the rpoB gene or due to some unknown mecha-
nism.20,35,36 Speciﬁc mutations in HSR and N-terminal region also
show variations depending upon the ethnicity of TB patient/
geographical location where M. tuberculosis strain is
isolated.30e34,36
Missense mutations at rpoB codon 511, 518 or 522 cause low-
level while those at codon 516, 526 or 531 cause high-level RIF
resistance.35,37 Also, a relationship exists between speciﬁc rpoB
mutations and cross-resistance of M. tuberculosis isolates to other
rifamycins. Isolates withmutations at codon 511 or 533 exhibit low-
level RIF resistance but remain susceptible to rifabutin (RBU) while
those with mutations at codon 514, 515, 516, 522 or 533 become
RIF-resistant but remain susceptible or exhibit low-level resistance
to RBU. However,M. tuberculosis isolates with rpoBmutations in N-
terminal region or at codon 513, 526 or 531 exhibit high-level
resistance to both RIF and RBU.37,38 Thus, RBU may be used as
a second-line drug for the treatment of some patients infected with
RIF-resistant strains carrying speciﬁc rpoB mutations.
Pyrazinamide (PZA), a pro-drug, is highly effective against
semidormant bacilli in acidic environment (like macrophages).22,23
The PZA is activated by pyrazinamidase encoded by pncA gene to
pyrazinoic acid which, by lowering intracellular pH, inactivates
a vital fatty acid synthase. The PZA is highly speciﬁc against
M. tuberculosis, other mycobacteria are intrinsically resistant to PZA
due to lack of an efﬁcient pyrazinamidase. Similar to INH, most
PZA-resistantM. tuberculosis strains also contain mutations in pncA
gene that activates the pro-drug.39,40 Nearly 20e30% of PZA-resis-
tant M. tuberculosis strains contain wild-type pncA, suggesting the
existence of other resistance conferring mechanism(s).23,39,40
Ethambutol (EMB) is now used in place of SM in combination
therapy with INH, RIF and PZA since resistance of M. tuberculosis
strains to EMB is much less compared to SM.1,9,13 The molecular
basis of resistance to EMB is not fully deﬁned. The EMB mainly
targets enzymes participating in synthesis and polymerization of
cell wall arabinan, and interacts with three homologous, membrane
associated arabinosyltransferases encoded by embCeembAeembB
genes.41 It also affects proteins encoded by isoniazid-inducible
genes like iniA and acyl carrier proteins and other proteins regu-
lating their expression.41,42 Mutations in embB, particularly at
embB306, embB406 and embB497 occur more frequently and confer
resistance to EMB.43,44 The frequency of embB306 mutations also
varies (20e70%) in EMB-resistant strains from different geograph-
ical locations (Table 2).41,42,45
Streptomycin (SM) is nearly as effective as EMB, however,
several factors have discouraged its use in more recent times. Oral
formulations in multidrug regimens are not feasible requiring
frequent patient’s visit to health care facilities. Globally, highest
level of resistance to an anti-TB drug is also observed for SM.9,13 The
SM may be used as a ﬁrst-line or second-line drug for treating
patients with failing therapy or MDR-TB provided the M. tubercu-
losis strain is susceptible to SM.7 The SM binds to a ribosomal
protein and 16S rRNA (encoded by rpsL and rrs, respectively)
causing misreading of mRNA and faulty protein synthesis. Since
M. tuberculosis genome contains a single rrs gene, nearly 30% of
SM-resistant M. tuberculosis isolates contain mutations in the rrs
gene.46,47 The remaining SM-resistant M. tuberculosis strains either
contain mutations in rpsL (at rpsL43 or rpsL88) or in other
genes.23,46,47
Other aminoglycosides, kanamycin (KAN) and amikacin (AMI)
also inhibit protein synthesis (peptide chain elongation) in
M. tuberculosis and are used as second-line injectable drugs for
actively dividing bacteria.2,7 Resistance to KAN and AMI is mainly
associated with rrs mutations. Although cross-resistance between
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either KAN or AMI is not reported, hence KAN/AMI may be used for
SM-resistant strains.48 However, cross-resistance between KAN/
AMI and other injectable agents such as capreomycin (CAP) and
viomycin (VIO) (cyclic peptides) has been described. The rrs
mutation A1401 G is associated with high-level KAN and AMI
resistance but usually causes low-level resistance to CAP and no
resistance to VIO while C1402 T is associated with high-level CAP
and VIO resistance but usually causes low-level resistance to KAN
and no resistance to AMI inM. tuberculosis.48 However, rrsmutation
G1484 T is associated with high-level resistance to CAP, VIO, KAN
and AMI.48 Another mechanism conferring resistance to CAP and
VIO involves mutations in the tlyA gene.49
Fluoroquinolones (FQs) such as oﬂoxacin (OFX) and levoﬂoxacin
(LFX) are important second-line drugs for treatingMDR-TB.1,9,15 The
new-generation FQs (moxiﬂoxacin, MFX and gatiﬂoxacin, GFX)
have excellent bactericidal activity against M. tuberculosis.50 The
FQs inactivate DNA gyrase (composed of two A and two B subunits
encoded by gyrA and gyrB genes, respectively) and inhibit DNA
replication.51 In M. tuberculosis, resistance to FQs is mainly associ-
ated with mutations at codons 90, 91 and 94 of gyrA gene.31,51e53
Some FQ-resistant M. tuberculosis strains contain mutations at
gyrB464 or gyrB495.52
Ethionamide (ETH), a structural analog of INH, is used as
a second-line drug for MDR-TB and shares the target with INH.
Similar to INH, ETH is also a pro-drug, however, it is activated by
a monooxygenase (encoded by ethA).54 The ethA catalyses a two
step activation of ETH to its active form (4-ethyl-4-amidopyridine).
Similar to INH and PZA, majority of ETH-resistant M. tuberculosis
strains contain mutations in ethA that abolish activation of pro-
drug.54 Similar to INH, the main cellular target of activated ETH is
inhA and mutations in inhA regulatory region that are associated
with INH resistance also cause cross-resistance to ETH.23,54
Diagnosis of active TB disease
The diagnosis of active disease (including pulmonary as well as
extrapulmonary TB) is usually based on clinical suspicion, chest
radiographs, smears for acid-fast bacilli (AFB), solid and liquid
culture and, more recently, hybridization- and PCR ampliﬁcation-
based detection ofM. tuberculosis nucleic acid in clinical specimens.
A brief outline for the diagnosis of active TB disease is described
here. Several review articles are available for a more detailed
description.6,55e57
Microscopic examination of smears for acid-fast bacilli for all
clinical specimens is a rapid and inexpensive test, however, it is
positive in only 34e80% of expectorated sputum samples and is
often negative in HIV-coinfected TB patients due to atypical
presentation.1,55 The sensitivity for non-sputum samples is even
less. Also, the test does not differentiate TB from infections caused
by non-tuberculous mycobacteria (NTM). The gold standard for TB
diagnosis is culture of M. tuberculosis. The culture also allows
species-speciﬁc identiﬁcation, DST to guide therapy and ﬁnger-
printing of isolates during epidemics. Culture on solid media takes
4e6 weeks while liquid media-based culture systems yield faster
(7e12 days) growth of M. tuberculosis.6 Phage-based assays devel-
oped more recently offer rapid detection of M. tuberculosis in
resource-poor settings.56
Molecular methods have provided rapid diagnosis of TB in
smear-negative specimens particularly when the organism can not
be grown in culture and also to rapidly differentiate culture-grown
M. tuberculosis from NTM.6,57 Two molecular tests are also
approved by FDA for respiratory specimens.57 In-house developed
PCR assays vary in their choice of ampliﬁcation target, detection
platforms, sensitivity and reliability of the results.6,57,58 Two reversehybridization-based assays allow identiﬁcation of M. tuberculosis
and several NTM species, both in cultured isolates and clinical
specimens.59e61 However, molecular tests have not been able to
replace microscopy and culture, but are rather used to conﬁrm the
presence of M. tuberculosis in positive sputum and non-sputum
smears.Diagnosis of MDR-TB
Rapid detection of drug resistance of M. tuberculosis and MDR-
TB strains ensures effective treatment of TB patients and limits
further development of resistance to additional drugs. The CDC
strongly encourages reporting of DST results within 30 days of
specimen collection.7 Recent developments have considerably
improved the diagnosis of drug-resistant TB and MDR-TB by both,
conventional (phenotypic) and molecular (genotypic) methods.Conventional (phenotypic) methods
Conventional (phenotypic) DST methods require culture and
detect the growth ofM. tuberculosis in the presence of anti-TB drugs
by one of three (proportion, resistance ratio or absolute concen-
tration) methods on solid media.6 The broth-based semiautomated,
radiometric BACTEC 460 TB system (Becton Dickinson) is regarded
as the gold standard for culture and DST of M. tuberculosis to both
ﬁrst- and second-line anti-TB drugs.62,63 The 460 TB system reports
DST results within 4e12 days from primary cultures, while solid
media-based methods require nearly 3 weeks. More recently
nonradioactive, fully automated liquid culture systems have been
developed for culture and DST of M. tuberculosis.63e65 Of these,
BACTEC MGIT 960 TB system has been more extensively used and
is considered equivalent to BACTEC 460 TB system in recovery
and DST of M. tuberculosis.63e65 Susceptibility cut-off values
for both, ﬁrst-line and second-line anti-TB drugs have been
determined.6,62e65 AlthoughMGIT 960 systemmay be used directly
on sputum samples, additional time and labor is needed for iden-
tiﬁcation of M. tuberculosis. The automated liquid culture systems
are expensive for developing countries. Other cost-effective
methods have been developed for resource-poor settings.
The liquid media-based microscopic observation drug suscep-
tibility (MODS) test is a low-cost, rapid and direct assay for
simultaneous detection and DST of M. tuberculosis in sputum
specimens. The test requires skills similar to those for smear
microscopy, detects M. tuberculosis-speciﬁc cording growth and
results are available within 2 weeks in most cases.66e68 The limi-
tation of MODS test are indirect identiﬁcation ofM. tuberculosis and
requirement for frequent (if not daily) microscopic observations.
The colorimetric methods are another alternative for detecting
drug-resistant M. tuberculosis strains.69 They are based on reduc-
tion of redox indicators that are added to culture medium during in
vitro growth of M. tuberculosis. The tetrazolium salt-based assay
utilizes 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) which is yellow in color in its oxidized form but, is
reduced to blue/purple colored compound during growth of
M. tuberculosis. This method has been evaluated for direct detection
of RIF resistance on smear-positive sputum samples with excellent
results.70 The resazurin microtitre assay is based on oxidation of
resazurin by a growing culture of M. tuberculosis in the presence
of anti-TB drugs.71 The nitrate reductase assay depends on ability of
viableM. tuberculosis to reduce nitrate to nitrite and the results are
usually available within 10 days.72 This simple assay provides rapid,
accurate and cost-effective detection of MDR-TB and has performed
well with smear-positive sputum samples.69,72 Unlike MODS,
a limitation of nitrate reductase assay is the possibility of false-
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organisms.
The phage-based assays use mycobacteriophages to infect live
M. tuberculosis in the absence and presence of anti-TB drugs and
detect the bacilli using either the phage ampliﬁcation assay or
production of light.56 The method based on detection of light uses
luciferase reporter mycobacteriophages (e.g. phAE142). Viable
M. tuberculosis growing in presence of anti-TB drug and infected
with phage phAE142 emit light in the presence of luciferin and are
identiﬁed as drug-resistant strains.73 The FAST Plaque TB-Response
(Biotec Laboratories Ltd.) assay detects drug resistance of
M. tuberculosis directly in sputum specimens. The method provides
rapid (within 2 days) and accurate results when compared with the
proportion method and the BACTEC radiometric method.74
Molecular (genotypic) methods
Molecular (genotypic) DSTmethods detect resistance associated
mutations in target genes of M. tuberculosis, provide results within
1e2 days and can be performed directly on smear-positive sputum
and other clinical samples.57,75,76 Although genotypic methods
have been developed for all ﬁrst-line and many second-line drugs,
detection of RIF resistance is more practical and a priority, since
90e95% RIF-resistant strains contain mutations in a small (81-bp)
region (HSR) of a single (rpoB) gene and RIF resistance is a surrogate
marker for MDR-TB.20,75e77 For other anti-TB drugs, the sensitivity
of resistance detection varies more widely due to the number of
gene loci involved and the sheer diversity of mutations.23 Still,
drug-resistant M. tuberculosis strains isolated from TB patients of
different ethnic background or from different geographical loca-
tions may exhibit few dominant mutations.26 Hence, prior knowl-
edge about the nature and frequency of resistance conferring
mutations is critical to develop region-speciﬁc molecular diag-
nostic methods. Alternatively, assays targeting entire gene or
multiple gene loci in a single test may be utilized.40,78e80 Several
methods have been developed and evaluated for the detection of
resistance conferring mutations in MDR-TB strains.
The PCR-restriction fragment length polymorphism (PCR-RFLP)
analysis is a simple, rapid and inexpensive method to detect
polymorphism at a single or few codons that are mutated in drug-
resistant strains.81e83 The PCR-RFLP has been mostly used for the
detection of katG315 and embB306mutations for rapid detection of
INH and EMB resistance, respectively.45,83
The DNA sequencing provides unambiguous detection of
mutations. Results of resistance detection by other methods have
traditionally been conﬁrmed by DNA sequencing of target gene
region/codon. Direct DNA sequencing of gene target is most prac-
tical if majority of drug-resistant strains contain mutations in
a limited region of a single target gene. This is particularly true for
RIF (>90% RIF-resistant strains contain mutations in HSR of rpoB
gene) and PZA (due to small size of pncA gene).20,39 Also, most INH-
resistant strains from some geographical locations contain muta-
tions at katG315.26,83 Thus, targeted DNA sequencing has been
applied for the detection of mutations conferring resistance to RIF,
INH and PZA. The DNA sequencing is still considered as impractical
in most developing countries for analyzing large number of speci-
mens. However, recent technological advances may lead to rapid,
accurate and cost-effective analysis of DNA sequences for detection
of MDR M. tuberculosis strains.84
Real-time PCR assays have also been developed for rapid diag-
nosis of MDR-TB in smear-positive sputum specimens by detecting
mutations in rpoB, katG and regulatory region of inhA gene.85,86 A
commercial real-time PCR-based assay has now become available
for RIF resistance detection in both smear-positive and smear-
negative sputum samples (Xpert MTB, Cepheid). Since RIFresistance is a surrogate marker for MDR-TB, the positive test will
also detect w90% of MDR-TB strains from most geographical
locations.
The reverse hybridization-based line probe assays (macro-
arrays) and microarray-based assays have also been developed for
detection of MDR-TB strains directly in clinical specimens. There
are two commercially available DNA macroarray assays for detec-
tion of MDR M. tuberculosis. The INNO-LiPA Rif. TB assay (Innoge-
netics) detects mutations in HSR of rpoB gene.75,87 Since RIF
resistance is a surrogate marker for MDR-TB, the positive result also
predicts MDR status ofw90%M. tuberculosis strains. The GenoType
MTBDRplus (Hain Lifesciences) assay detects MDR-TB by simulta-
neously detecting mutations in HSR of rpoB gene for RIF resistance
and mutations at katG315 and inhA regulatory region for INH
resistance.76,88,89 Although expensive, these assays have performed
satisfactorily in high incidence countries for detection of MDR
M. tuberculosis in clinical samples within one working day.87,89
Recently, line probe assays have also been developed for detect-
ing resistance of M. tuberculosis to PZA and FQs.40,90 Other
hybridization-based assays involve microarrays and have been
tested for detecting resistance to RIF, INH, and EMB by using several
probes simultaneously.80,91 Some microarray-based assays are now
commercially available (Autogenomics).
Treatment and management of TB and MDR-TB
The drugs currently being used for the treatment of TB and
MDR-TB are listed in Table 3. First-line drugs (INH, RIF, PZA and
EMB) are mainly bactericidal, highly efﬁcacious and relatively less
toxic. Second-line drugs are mainly bacteriostatic, less effective,
costly and have more drug-associated adverse effects.7 These
include aminoglycosides (kanamycin, KAN; amikacin, AMI and
streptomycin, SM), the polypeptides (capreomycin, CAP and
viomycin, VIO), the thioamides (ethionamide, ETH and prothiona-
mide, PTH), several ﬂuoroquinolones (FQs) (such as oﬂoxacin, OFX;
levoﬂoxacin, LFX; moxiﬂoxacin, MFX; and gatiﬂoxacin, GFX), para-
amino salicylic acid (PAS) and D-cycloserine (CS).7,9 The SM is now
regarded as a second-line drug due to higher rates of resistance of
M. tuberculosis isolates to SM and the availability of more effective
anti-TB drugs.7 Rifabutin (RBU) may be used as a second-line drug
for some RIF-resistant M. tuberculosis strains. The new-generation
FQs (MFX and GFX) are bactericidal and are being considered as
ﬁrst-line agents.50,92 Some other drugs that are notM. tuberculosis-
speciﬁc but exhibit signiﬁcant in vitro and/or in vivo activity are also
being used for the treatment of MDR-TB and XDR-TB. These third-
line or reinforcing agents (Table 3) include clarithromycin (CLR),
clofazimine (CFZ), amoxicillin-clavulanic acid (AMX-CLV) and
linezolid (LZD).17,93,94
The ﬁrst-line drugs, INH and RIF are the back bone of treatment
for TB. If resistance develops to either of the two drugs, the patients
can still be successfully managedwith the available drugs, although
treatment duration is increased, particularly for infections caused
by RIF-resistant strains.95 Among clinical M. tuberculosis isolates,
monoresistance to INH is common while monoresistance to RIF
occurs infrequently except in HIV-coinfected TB patients and is
regarded as a surrogate marker for MDR-TB.9,20 Although infections
caused by INH monoresistant strains can be effectively managed
with available ﬁrst-line and other drugs, both treatment duration
and treatment failure are slightly higher compared to TB caused by
fully susceptible strains.7,95 However, infections caused by RIF-
resistant M. tuberculosis strains have poor prognosis compared to
drug-susceptible TB mainly because RIF is most-effective drug
against persisting bacilli that are mainly responsible for clinical
relapse. Increasing treatment duration to 12 months with anti-TB
drugs results in better prognosis.7,95
Table 4
Potential regimens for the treatment of patients with MDR-TB and XDR-TB.
Different patterns of
resistance to anti-TB drugs
Appropriate therapy
regimens
Total duration
of treatment,
months
Desirable
number of
active
drugs for
favorable
outcome
None INH, RIF, PZA, EMB 6 4
INH RIF, PZA, EMB and/or FQ 6e9 4
RIF INH, PZA, EMB, SM FQ 9e12 4e5
INH, RIF PZA, EMB, FQ, INJ SLD 18e24 5e6
INH, RIF, EMB PZA, FQ, INJþ SLD 18e24 5e6
INH, RIF, PZA EMB, FQ, INJþ SLD 24 5e7
INH, RIF, PZA, EMB FQ, INJþ SLD 24 5e7
INH, RIF, PZA, EMB, FQ INJþ SLDþ TLD >24 5e7
INH, RIF, PZA, EMB, INJ FQþ INJaþ SLDþ TLD >24 5e7
INH, RIF, PZA, EMB, FQ, INJ INJaþ SLDþ TLD >24 5e7
INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; SM, strepto-
mycin; FQ, ciproﬂoxacin or oﬂoxacin or levoﬂoxacin or moxiﬂoxacin or gatiﬂoxacin;
INJ, injectable agents like SM or kanamycin or amikacin or capreomycin or
viomycin; SLD, second-line drugs like rifabutin, ethionamide, prothionamide, para-
amino salicylic acid, D-cycloserine and thiacetazone; TLD, third-line drugs like CLR,
clarithromycin; AMX-CLA, amoxicillin b-lactam antibiotic with clavulanate b-laca-
tamase inhibitor; CFZ, clofazimine; and LZD, linezolid.
a Capreomycin or viomycin may be used for kanamycin or amikacin or vise versa
if no cross-resistance is observed.
Table 3
Some important anti-tubercular drugs and their mode of action.
Drug(s) Chemical description Route Class Mode of action Biological process inhibited
INH Nicotinic acid hydrazide Oral First-line Bactericidal Mycolic acid synthesis
RIF Rifamycin derivative Oral First-line Bactericidal Protein synthesis
PZA Nicotinamide derivative Oral First-line Bactericidal Unknown
EMB Ethylene diimino di-1-butanol Oral First-line Bacteriostatic Lipid/cell wall synthesis
RBU Rifamycin derivative Oral Second-line Bactericidal Protein synthesis
SM Aminoglycoside Injectable Second-line Bactericidal Protein synthesis
KAN/AMI Aminoglycoside Injectable Second-line Bactericidal Protein synthesis
CAP/VIO Cyclic peptide Injectable Second-line Bactericidal Protein synthesis
CIP/OFX Fluoroquinolone Oral Second-line Bacteriostatic DNA replication
LFX Fluoroquinolone Oral Second-line Likely bactericidal DNA replication
MFX/GFX Newer ﬂuoroquinolone Oral Second-line Bactericidal DNA replication
ETH/PTH Isonicotinic acid derivative Oral Second-line Bacteriostatic Mycolic acid synthesis
PAS Para-amino salicylic acid Oral Second-line Bacteriostatic Unknown
CS D-Cycloserine Oral Second-line Bacteriostatic Cell wall synthesis
TAC Thiacetazone Oral Second-line Bacteriostatic Mycolic acid synthesis
CLR Erythromycin derivative Oral Third-line Bactericidal Protein synthesis
AMX-CLA b-lactam with b-lactamase inhibitor Oral Third-line Bactericidal Cell wall synthesis
CFZ Iminopherazine derivative Oral Third-line Bacteriostatic Cell membrane function
LZD Oxazolidinone derivative Oral Third-line Bactericidal Protein synthesis
INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; RBU, rifabutin; SM, streptomycin; KAN, kanamycin; AMI, amikacin; CAP, capreomycin; VIO, viomycin; CIP,
ciproﬂoxacin; OFX, oﬂoxacin; LFX, levoﬂoxacin, MFX, moxiﬂoxacin; GFX, gatiﬂoxacin; PAS, para-amino salicylic acid; CS, D-cycloserine; TAC, thiacetazone; CLR, clari-
thromycin; AMX-CLA, amoxicillin b-lactam antibiotic with clavulanate b-lacatamase inhibitor; CFZ, clofazimine; LZD, linezolid.
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RIF (MDR-TB), treatment is much more difﬁcult, particularly in
HIV-TB coinfected patients. The treatment for MDR-TB requires
more extensive usage of second-line drugs and lasts for nearly two
years. The treatment for MDR-TB isw100 times more costly, many
of the second-line drugs are highly toxic and more likely to cause
adverse drug reactions, undesirable interactions occur with anti-
retroviral drugs in HIV-coinfected TB patients and much higher
relapse and mortality rates are observed compared to drug-
susceptible TB.7,95e97 Although initial outbreaks of MDR-TB resul-
ted in very high mortality rates, subsequent advances in diagnosis
and optimization of therapy regimens in industrialized countries
greatly improved clinical outcome, even in HIV-positive TB patients
receiving antiretroviral drugs.98e100 Recent developments in rapid
diagnosis of MDR-TB, prompt institution of aggressive therapy with
several active drugs, close radiological and bacteriological (for
sputum smear and culture) monitoring of patients have resulted in
further improvement in clinical outcome and lower mortality rates
in both HIV-negative and HIV-coinfected TB patients.101e103 The
suggested therapy regimens and average duration of treatment for
infections with MDR M. tuberculosis strains resistant to different
combinations of anti-TB drugs are listed in Table 4.
Current guidelines for successful management of patients
require treating centers to be equipped with rapid diagnostic
procedures for MDR-TB detection and universal DST for ﬁrst- and
second-line drugs.66,104e106 Due to poor prognosis, rapid diagnosis
of MDR-TB is even more critical in HIV-coinfected individuals,
however, conventional diagnostic methods lack sensitivity due to
lower sputum-smear positivity and atypical presentation.3,104,106
Molecular methods, if available, should be used for rapid detec-
tion and DST to guide therapy. The DST proﬁle is crucial for tailoring
individualized treatment regimens (ITRs) and for monitoring
response to treatment during therapy for MDR-TB. Studies have
shown that ITRs guided by DST results have better clinical outcome
even in developing countries.105,107,108 In developing countries that
lack universal culture and DST facilities, epidemiological informa-
tion, prior treatment history and poor response to current
TB treatment may help in the diagnosis of MDR-TB. In some
resource-poor countries with limited infrastructure, culture and
DST are being performed by a regional/national laboratory.109 It has
also been observed that a proactive approach to identify MDR-TBcases optimizes therapy with more aggressive initial drug regi-
mens. Early initiation of therapy regimens containing several (4e6
or even more) drugs, not previously taken and thus more likely to
be effective, has a more favorable outcome for MDR-TB while
delaying therapy results in higher mortality rates.7,97,110 Therapy
regimens that include a new-generation FQ (MFX or GFX), an
injectable agent and bactericidal second-line drugs with manage-
able side effects are associated with better clinical outcome. Studies
have also shown that therapy with insufﬁcient number of second-
line drugs while awaiting DST results may actually result in
acquisition of resistance to additional drugs.101,111
In addition to aggressive therapywith 5e7 drugs in initial phase,
other factors also inﬂuence rapid sputum conversion and improve
treatment outcome. These include therapy for>3months with 6 or
more active drugs, use of an effective injectable agent for >6
months, oral treatment for >18 months and initial resistance to
S. Ahmad, E. Mokaddas / Respiratory Medicine CME 3 (2010) 51e61 57fewer drugs.97,110,112 Regular (once a month) monitoring of sputum
specimens for smear microscopy, culture and DST indicates
response to treatment and should be carried out until sputum
culture conversion has been achieved. Early sputum culture
conversion (within 2 months of initiating therapy) is associated
with better clinical outcome while patients who remain sputum
culture-positive at three months are more likely to have poor
prognosis.110,112 Continued sputum smear and culture positivity
without clinical improvement usually indicate ineffective therapy
or poor adherence to treatment and warrant fresh DST and reas-
sessment of treatment strategies.101,110
Directly observed therapy (DOT) support for MDR-TB patients
ensures adherence to treatment regimens and rapid adjustments to
avoid adverse drug reactions minimize the risk of default. This is
best achieved in hospital settings, since inpatient management
allows closemonitoring for adverse drug reactions and also ensures
patient’s adherence to treatment.113,114 However, recent studies
have shown that successful treatment of MDR-TB patients can also
be achieved in community settings even in developing
countries.115e117 Community-based treatment decreases the chan-
ces for nosocomial transmission of infection to other patients and
health care workers.
The treatment of MDR-TB has been markedly less successful in
developing countries due to lack of rapid diagnostic methods,
universal culture and DST facilities and availability of second-line
drugs. Retreatment of patients under WHO’s DOTS strategy in
endemic countries for MDR-TB has been largely ineffective and has
actually resulted in emergence of additional resistance.95e97 The
WHO and its international partners have now evolved DOTS-Plus
strategy for better treatment of MDR-TB patients in developing
countries.118 The WHO’s Green Light Committee (GLC) has subsi-
dized drug prices but have also exerted strict control on availability
of second-line drugs. However, only w10% of MDR-TB cases in
developing countries are currently being treated under the GLC
program. Thus, greater distribution of quality-assured drugs,
universal culture and DST availability for initial diagnosis and for
monitoring response to therapy will be required to substantially
decrease the overall burden of MDR-TB in resource-poor settings.
Successful treatment of XDR-TB ismuchmore difﬁcult thanMDR-
TBeven indevelopedcountriesand involves therapywithall available
ﬁrst-, second- and third-line drugs, close monitoring of patients for
adversedrugreactionsandother interventions suchassurgery.93,94 In
developing countries, XDR-TB is virtually an untreatable disease and
all efforts should be made to minimize its emergence by successful
treatment of the existing MDR-TB cases. Modeling studies have
shown that emergence of XDR-TB can be avoided by proper
management of MDR-TB.17 However, treatment and management of
MDR-TB can not be accomplished without local laboratory capacity
for sputum culture, DST and close monitoring of patients for adher-
ence to treatment regimens and for adverse drug reactions.
Promising new anti-TB drugs
Rifampin was the last TB-speciﬁc drug introduced in combina-
tion therapy regimens and was instrumental, due to its activityTable 5
Some promising anti-tubercular drugs in various stages of development.
Potential drug Active or Pro-drug Description
PA-824 Pro-drug Nitroimidazo-oxazine
OPC-67683 Pro-drug Nitroimidazo-oxazole
R207910 Active Diarylquinoline
SQ109 Active Ethylenediamine derivat
Compound 5 Pro-drug Quinoxaline-oxide deriva
Compound 7 g Unknown Quinoline-isoxazole deriagainst non-replicating persistent bacteria, in reducing the dura-
tion of chemotherapy to six months which has remained
unchanged for nearly forty years.5,119 The incomplete eradication of
non-replicating persistent bacilli is a major factor for relapse or
treatment failure in TB patients not adhering to therapy.119,120 To
overcome this phenotypic drug resistance, strict monitoring of
treatment under DOTS strategy with four ﬁrst-line drugs for six
months was instituted. However, this labor-intensive strategy for
an extended period of time has been too difﬁcult to implement on
a nationwide scale for many countries resulting in development of
drug-resistant and MDRM. tuberculosis strains.1 The search for new
anti-TB drugs aims to shorten the treatment duration of drug
sensitive active TB to 2 months. Mathematical modeling studies
have shown that nearly a fourth of new TB cases and TB-related
deaths could be avoided with the introduction of a 2 month
regimen in South-Southeast Asia alone.121 The worldwide emer-
gence of MDR-TB and XDR-TB has also accelerated the search for
novel drugs against new targets that will be effective against MDR
and XDR M. tuberculosis strains.
New anti-TB drugs, to be effective, must have potency greater
than the most active drugs currently available against actively
dividing and non-replicating persistent bacteria (exempliﬁed by
INH and RIF, respectively, in the current treatment regimens). The
substitution of EMB by newer ﬂuoroquinoloes (MXF and GFX) in
the standard treatment regimens shows promise to shorten the
duration of treatment from the current 6 months to 4 months.122
Several new anti-TB drugs (Table 5) are at various stages of devel-
opment for the treatment of drug sensitive active TB, MDR-TB and
XDR-TB.
The PA-824, a nitroimidazo-oxazine pro-drug of nitroimidazole
class is a promising new compound and is currently undergoing
Phase II clinical trials for drug sensitive TB.123,124 This drug requires
bioreductive activation to exert its antitubercular effect. The PA-824
is equally active against drug sensitive as well as MDR M. tubercu-
losis strains and is also active against non-replicating persistent
bacteria, making it an ideal drug candidate to shorten treatment
duration.123,124 The OPC-67683, a nitroimidazo-oxazone pro-drug
of nitroimidazole class is another promising new compound and is
currently undergoing Phase II clinical trials for the treatment of
MDR-TB.125 Although both PA-824 and OPC-67683 are activated by
the same mechanism, their cellular targets are different. In vitro
generated PA-824-resistant strains have identiﬁed a conserved
hypothetical protein (Rv3547) of M. tuberculosis as the main target
of PA-824. Although the exact function of the target protein is not
known at present, the PA-824-resistantM. tuberculosis strains with
mutations in Rv3547 remained sensitive to nitroimidazo-
oxazines.126
The drug R207910 (also known as TMC207) is a diarylquinoline
that inhibits adenosine triphosphate (ATP) synthase.127 This novel
compound has excellent activity against both, drug sensitive as well
as MDR M. tuberculosis strains.128 In animal models, R207910 has
shownmore potent early bactericidal activity than INH during early
phase of infection and higher bactericidal activity late in infection
than RIF alone.127 The activity of R207910 against both, actively
dividing and non-replicating persistent bacteria suggests that thisCellular process inhibited Stage of development
Mycolic acid synthesis Phase II
Mycolic acid synthesis Phase II
ATP synthesis Phase II
ive Lipid/cell wall synthesis Phase I
tive Unidentiﬁed Preclinical
vative Unidentiﬁed Preclinical
S. Ahmad, E. Mokaddas / Respiratory Medicine CME 3 (2010) 51e6158anti-TB drug also has great potential to shorten the duration of
treatment for drug sensitive as well as MDR-TB.128 Phase II clinical
trials are currently being conducted to evaluate its safety and efﬁ-
cacy in combination therapy with standardized second-line treat-
ment regimen for MDR-TB.
The 1,2-ethylenediamine (also known as SQ109) is structurally
related to ﬁrst-line drug, EMB.129 However, its mechanism of action
appears to be different than that of EMB as the drug has in vitro
bactericidal activity against EMB-resistant M. tuberculosis strains.
The drug also exhibits synergistic bactericidal action with INH and
RIF and has now entered phase I clinical trials for dose-dependant
efﬁcacy studies.129,130
Several other new anti-TB drugs have also shown promising
results for both, drug sensitive and drug-resistant M. tuberculosis
strains. Notable among these are compound 5, a quinoxaline-oxide
derivative and compound 7 g, a quinoline-isoxazole derivative
(Table 5).131,132 Both drugs have shown submicromolar and
micromolar bactericidal activities against actively dividing and
non-replicating persistent bacteria, respectively, under in vitro
conditions. If these ﬁndings are also replicated under in vivo
conditions, these drugs will add further to the promising leads for
new anti-TB drug development. Hopefully, some of these drugs will
be ﬁnally approved for the treatment and proper management of
MDR-TB.
Conclusion
The current MDR-TB epidemic is the result of decades of neglect
for an important infectious disease, lack of resources for national TB
control programs, poor case detection and inadequate/inappro-
priate therapy in high-burden countries. Initial outbreaks of MDR-
TB in developed countries were associated with very highmortality
rates both in HIV-negative and HIV-coinfected patients. Optimiza-
tion of treatment regimens together with rapid diagnosis and DST
for ﬁrst- and second-line drugs, greatly improved the clinical
outcome. Recent advances in diagnosis of MDR-TB and aggressive
empirical treatment of patients with several drugs in the initial
phase of treatment have further improved the prognosis of MDR-
TB. However, in developing countries, the prognosis is still largely
poor due to inadequate laboratory support that is critical for
successful management of MDR-TB patients. Rapid and cost-
effectivemethods for culture and DSTofM. tuberculosis strains have
recently been developed that are suitable for resource-poor
countries. The new anti-TB drugs that are in various stages of
development also offer hope that we will not soon run out of
treatment options against TB and MDR-TB.
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charge).Educational questions
Answer the following questions:
1. Multi drug resistant TB (MDR-TB) continues to increase in all
countries.
a. True
b. False
2. MDR-TB occurs in what percent of all TB world-wide?
a. 1%
b. 5%
c. 10%
d. 15%
e. >15%
3. When treating a new case of TB from a patient highly suspected
for MDR-TB, it is appropriate to wait for results of DST if rapid
assessment of MDR is not available.
a. True
b. False
4. Treatment of MDR-TB can succeed with direct observation
treatment given at which site?
a. as hospital inpatient
b. during daily clinic visits
c. in the community
d. all of the above
5. The two factors that are sustaining the current world wide TB
epidemic are:
a. MDR-TB and poverty
b. MDR-TB and lack of rapid MDR testing
c. MDR-TB and lack of effective drugs
d. MDR-TB and HIV infectionsReferences
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